NCT Number: NCT04068038
Mortality rates in children with pediatric acute respiratory distress syndrome (PARDS) are higher in Asia compared to other regions. In adults with acute respiratory distress syndrome, the only therapy that improves mortality rates is a lung protective ventilation strategy. The pediatric ventilation recommendations are extrapolated from evidence in adults, including ventilation with low tidal volume, low peak/plateau pressures and high-end expiratory pressure. A recent retrospective study of ventilation practices in Asia showed varying practices with regards to pulmonary and non-pulmonary therapies, including ventilation. This study aims to determine the prevalence and outcomes of PARDS in the Pediatric Acute and Critical Care Medicine Asian Network (PACCMAN). This study will also determine the use of pulmonary (mechanical ventilation, steroids, neuromuscular blockade, surfactant, pulmonary vasodilators, prone positioning) and non-pulmonary (nutrition, sedation, fluid management, transfusion) PARDS therapies. To achieve this aim, a prospective observational study which involves systematic screening of all pediatric intensive care unit (PICU) admissions and collection of pertinent clinical data will be conducted. Recruitment will be consecutive and follow up will continue to intensive care discharge.
Looking for future studies?
Notify MeUp to 21 year
All sexes
Observational
Guangzhou Women and Children's Medical Center, Guangzhou, China
The overall objective of this study is to prospectively determine the epidemiology of children with PARDS and describe its management in Asia. The first specific aim is to determine the prevalence of PARDS among PICU admissions. This will be achieved by establishing a systematic manner of screening patients and including them in this study. The second specific aim is to describe the use of pulmonary and non-pulmonary therapies in PARDS. This study will utilize an established dataset to extract pertinent and analyzable clinical data.The third specific aim is to determine the outcome of patients with PARDS. These outcomes will include functional data, PICU mortality, ventilator duration and length of stay data. This is a two-part study - the first part to establish the baseline prevalence and ventilator management strategies, the second part will include the implementation of an evidence based ventilation protocol as part of routine care. The same screening process, eligibility criteria and data collection will apply throughout the two parts. We aim to obtain data for approximately 2years prior to and 2years subsequent to the implementation of the ventilator protocol.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
Time frame: Through study completion
Number of participants diagnosed with PARDS over number of intensive care admissions
Time frame: up to 60 days
Number of PARDS participants who died over number of participants diagnosed with PARDS
Time frame: up to 28 days
Number of days alive and free of mechanical ventilation
Time frame: up to 28 days
Number of days alive and discharge from the intensive care unit
Time frame: up to 28 days
Number of participants who require ECMO
Time frame: up to 60 days
Number of PARDS participants who died or required ECMO over total number of participants diagnosed with PARDS
Time frame: up to 60 days
Mortality and secondary outcomes excluding limitation of care orders
KK Women's and Children's Hospital
Other Gov
Pediatric Acute Respiratory Distress Syndrome: a Prospective Asian Multicenter Study
Acronym: PARDS Asia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05922631
Acute Respiratory Distress Syndrome, Cardiovascular Diseases
Wuhan, Hubei, China
View Trial DetailsNCT03920189
Acute Respiratory Distress Syndrome, Echocardiographic Ultrasound
Milan, Italy
View Trial DetailsNCT04443491
Acute Respiratory Distress Syndrome, Lung Diseases
Siena, Italy
View Trial DetailsNCT02545621
Acute Respiratory Distress Syndrome, Lung Diseases
Clermont-Ferrand, France
View Trial Details